IRF4 as a Tumor Suppressor in B Cell Leukemia
Author Information
Author(s): Pathak Simanta, Ma Shibin, Trinh Long, Eudy James, Wagner Kay-Uwe, Joshi Shantaram S., Lu Runqing
Primary Institution: University of Nebraska Medical Center
Hypothesis
IRF4 functions as a tumor suppressor against c-Myc induced B cell leukemia.
Conclusion
IRF4 suppresses c-Myc induced leukemia, and its deficiency accelerates the disease in mice.
Supporting Evidence
- IRF4+/−Myc mice showed a median age of mortality of 7 to 8 weeks compared to 20 weeks in control mice.
- Leukemic cells in IRF4+/−Myc mice were derived from large pre-B cells and were hyperproliferative.
- Restoration of IRF4 expression in leukemic cells induced p27kip and inhibited their expansion.
Takeaway
IRF4 helps keep B cells healthy and stops them from turning into cancer cells. When IRF4 is missing, the B cells can grow too fast and become cancerous.
Methodology
The study involved breeding IRF4 deficient mice with EμMyc transgenic mice to assess the role of IRF4 in leukemia development.
Limitations
The study primarily focuses on mouse models, which may not fully replicate human disease.
Participant Demographics
Mice aged 5 to 30 weeks were used in the study.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website